Momenta Pharmaceuticals Inc. (NASDAQ: MNTA) was started as Overweight at JPMorgan on Friday, and the firm assigned a $26 price target. This implied 46% upside from the prior $17.76 close, although Momenta shares rose …
The stock has increased 36 percent in the last 12 months. This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on MNTA …
This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on MNTA at https://www.zacks.com/ap/MNTA Keywords: Momenta …
Momenta Pharmaceuticals (NASDAQ:MNTA) shifted sharply into reverse in early trading ... Momenta's multiple sclerosis treatment. Analysts that follow the stock had expected revenue of $30.42mln. The shares shed 8.3% at $10.55. “The …
The stock decreased 0.13% or $0.02 during the last trading session ... It also reduced its holding in Momenta Pharmaceuticals (NASDAQ:MNTA) by 235,599 shares in the quarter, leaving it with 264,699 shares, and cut its stake …
AnaptysBio, Inc., a privately-held therapeutic antibody company, today announced that Momenta Pharmaceuticals, Inc. …
Shares of Momenta Pharmaceuticals Inc. MNTA were down 12.6% after the company reported disappointing ... However, revenues were down 17.3% from the year-ago quarter. Momenta’s stock has decreased 15.1% year to date compared …
Momenta Pharmaceuticals (NASDAQ:MNTA) shifted sharply into reverse in early trading ... Momenta's multiple sclerosis treatment. Analysts that follow the stock had expected revenue of $30.42mln. The shares shed 8.3% at $10.55. “The …
MNTA) jumped after the company reported positive results from a drug trial. Image source: Getty Images. Bookseller Barnes & Noble reported a decline in holiday sales that was worse than expected, and its stock plummeted 14.2%. …